Tech Company Inital Public Offerings
Versartis IPO
Operating out of Mountain View, Versartis went public.
Transaction Overview
Company Name
Announced On
3/21/2014
Transaction Type
IPO
Amount
$126,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
275 Shoreline Dr. 450
Mountain View, CA 94065
USA
Mountain View, CA 94065
USA
Phone
Website
Email Address
Overview
Versartis (NASDAQ: VSAR) is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Shepard
Chief Financial Officer
Joshua Brumm
Chief Medical Officer
George Bright
VP - Bus. Development
Paul Westberg
VP - Manufacturing
Patrick Murphy
VP - Operations
Eric Humphriss
VP - Product Management
Rajendra Mohabir
Browse more venture capital transactions:
Prev: 3/21/2014: Pley venture capital transaction
Next: 3/21/2014: Saffron Technology venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs